The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Anagrelide for Essential Thrombocythemia

Selective platelet-lowering agent for high-risk myeloproliferative neoplasm

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Anagrelide for Essential Thrombocythemia?

Anagrelide is a phosphodiesterase 3 inhibitor that selectively reduces platelet counts by impairing megakaryocyte maturation.

Used as second-line therapy in essential thrombocythemia (ET) when hydroxyurea is contraindicated, intolerated, or ineffective.

Younger patients particularly considered for anagrelide to avoid long-term hydroxyurea-related leukemogenic concerns.

Does not appear to increase risk of acute myeloid leukemia transformation in long-term studies.

Compared to hydroxyurea, anagrelide may offer comparable platelet control but slightly higher arterial thrombosis risk in JAK2-positive patients.

Symptoms

Symptoms of ET: thrombosis (arterial or venous), bleeding, headache, vasomotor symptoms.
Treatment-related: palpitations, fluid retention, headache, diarrhea (most common).
Cardiac symptoms: tachycardia, congestive heart failure rarely with high doses.
Anemia in some patients during prolonged therapy.
Renal dysfunction in elderly with prior kidney disease.

Risk Factors

Essential thrombocythemia diagnosis with high-risk features (age over 60, prior thrombosis, very high platelets).
Hydroxyurea intolerance or resistance.
Younger patients prioritizing leukemogenic risk reduction.
Pregnancy is a contraindication; safer alternatives (interferon) preferred.
Cardiovascular comorbidities require dose caution.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Symptoms of thrombosis: chest pain, leg swelling, sudden vision changes.
  • Bleeding episodes despite cytoreduction.
  • Worsening palpitations, dyspnea, or new edema.
  • Severe diarrhea or fluid retention not responding to dose reduction.
  • Pregnancy planning while on anagrelide therapy.

Treatment Methods

01
Starting dose anagrelide 0.5 mg orally twice daily (1 mg total daily).
02
Dose titration to lowest effective dose maintaining platelets less than 600 per microliter.
03
Maximum daily dose 10 mg, with most patients responding at 1 to 4 mg daily.
04
Cardiac monitoring at baseline (echocardiogram, ECG) and periodically during therapy.
05
Switch to interferon alfa or pegylated interferon during pregnancy planning.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.